Company Quick10K Filing
Capstone Therapeutics
10-Q 2019-06-30 Filed 2019-08-13
10-Q 2019-03-31 Filed 2019-05-13
10-K 2018-12-31 Filed 2019-03-22
10-Q 2018-09-30 Filed 2018-11-06
10-Q 2018-06-30 Filed 2018-08-13
10-Q 2018-03-31 Filed 2018-05-11
10-K 2017-12-31 Filed 2018-02-28
10-Q 2017-09-30 Filed 2017-11-13
10-Q 2017-06-30 Filed 2017-08-14
10-Q 2017-03-31 Filed 2017-05-04
10-K 2016-12-31 Filed 2017-03-15
10-Q 2016-09-30 Filed 2016-11-10
10-Q 2016-06-30 Filed 2016-07-29
10-Q 2016-03-31 Filed 2016-05-13
10-K 2015-12-31 Filed 2016-03-30
10-Q 2015-09-30 Filed 2015-11-09
10-Q 2015-06-30 Filed 2015-08-13
10-Q 2015-03-31 Filed 2015-05-14
10-K 2014-12-31 Filed 2015-03-16
10-Q 2014-09-30 Filed 2014-11-13
10-Q 2014-06-30 Filed 2014-08-14
10-Q 2014-03-31 Filed 2014-05-15
10-K 2013-12-31 Filed 2014-03-27
10-Q 2013-09-30 Filed 2013-11-12
10-Q 2013-06-30 Filed 2013-08-14
10-Q 2013-03-31 Filed 2013-05-15
10-K 2012-12-31 Filed 2013-03-14
10-Q 2012-09-30 Filed 2012-11-08
10-Q 2012-06-30 Filed 2012-08-10
10-Q 2012-03-31 Filed 2012-05-10
10-K 2011-12-31 Filed 2012-03-21
10-Q 2011-09-30 Filed 2011-11-10
10-Q 2011-06-30 Filed 2011-08-12
10-Q 2011-03-31 Filed 2011-05-13
10-K 2010-12-31 Filed 2011-03-29
10-Q 2010-09-30 Filed 2010-11-10
10-Q 2010-06-30 Filed 2010-08-09
10-Q 2010-03-31 Filed 2010-05-14
10-K 2009-12-31 Filed 2010-03-12
8-K 2019-08-22 Enter Agreement, Shareholder Rights, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2019-03-15 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-05-02 Enter Agreement, Regulation FD, Exhibits
8-K 2018-01-30 Enter Agreement, Off-BS Arrangement

Capstone Therapeutics Financials

CAPS Metrics, Comps, Filings

Quarterly | Annual

Business

Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.

On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, and/or an analog, as treatment for Homozygous Familial Hypercholesterolemia (granted Orphan Drug Designation by FDA in 2012), other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.

In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Northstar Electronics (NEIK) 1,278 -3.8 -730% 54 5,201 0 0 -391 -319 1,225
HST Global (HSTC) 1,274 2.8 2,050% 22 0 0 0 452 443 1,257
Spine Injury Solutions (SPIN) 1,214 24% -0.9 -75% 1,709 1,327 151 35 -1,279 -1,177 1,025
Sharing Economy International (SEII) 1,206 -93% -0.1 -198% 14,224 7,563 5,244 -4,862 -28,102 -27,274 1,857
Spectral Capital (FCCN) 1,179 0% -8.6 -21,809% 1 881 0 0 -137 -137 1,178
Argos Therapeutics (ARGS) 1,165 0% -1.3 -106% 10,881 23,454 8,905 0 -11,529 -8,973 11,710
Yulong Eco-Materials (YECO) 1,133 31% 0.0 -200% 33,278 29,559 10,084 3,137 -66,490 -64,932 -681
MicroChannel Technologies (MCTC) 29,418 -997.6 0 158 0 0 -29 -29 29,418
Capstone Therapeutics (CAPS) 1,088 -1.4 -315% 703 3,463 0 0 -2,216 -2,173 2,961
Franchise Holdings International (FNHI) 1,086 20% -9.2 -19% 848 1,267 1,448 293 -158 -103 950
Oncolix (ONCX) 1,085 -1.0 -2,427% 297 7,602 0 0 -7,200 -6,988 7,169
Q2Earth (QPWR) 1,040 0% 6.5 1,037% 15 4,036 3,142 0 159 159 1,037
ColorStars (CSTU) 1,023 100% -8.6 -119% 101 450 7 7 -121 -119 1,015
Arias Intel (ASNT) 1,014 -0.1 -1,260% 723 6,449 0 0 -9,111 -8,536 1,014
Altex Industries (ALTX) 984 0% -183.1 -1% 2,344 1,091 56 0 -32 7 -1,282
Propanc Biopharma (PPCB) 983 -1.0 -2,593% 198 4,739 0 -24 -5,125 -3,561 3,434
TX Holdings (TXHG) 961 16% 8.3 2% 2,141 4,095 3,935 621 42 174 1,438
Axion Power (AXPW) 960 -2,624% -0.1 -1,826% 578 8,143 58 -1,527 -10,558 -10,312 759
GeoVax Labs (GOVX) 956 0% -0.2 -218% 817 1,837 907 0 -1,780 -1,771 416
Virtual Crypto Technologies (VRCP) 922 98% -1.2 -271% 235 1,546 63 62 -638 -642 756

Balance Sheet ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-30
Cash19,60817,60813,77813,11712,82411,35510,2059,2018,1237,1836,2585,4904,1933,1112,1641,5401,0376371,0117186921,1277484864371,7181,2758052,2911,8161,3411,092305
Accounts Receivable
Inventory
PP&E214187160136342869413752552002550002550002550025551
Assets19,99218,00414,69613,78513,05812,73211,59110,4609,2298,1337,3176,5115,2834,0933,3852,7982,1341,5461,7671,4131,2001,5971,1828827582,0371,5691,0382,4201,9621,4771,221703
Accounts Payable38533777144812092333137420088253112225124185211132254173402325249324393157197203244415245630797
Long-Term Debt2,1592,1402,1282,1282,1282,1282,1782,178
Liabilities1,162764119156936914873341012061002884304712823653511881,2611,2661,4311,3691,3041,3911,4732,3522,4482,5022,6022,8322,7213,3163,463
Stockholders' Equity18,83017,24014,57713,62912,96512,04111,10410,1269,1287,9277,2176,2234,8533,6223,1032,4331,7831,358506147-231228-122-509-715-315-879-1,464-182-870-1,244-2,095-2,760
Income Statement ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-30
Revenue2,000000
Cost of Revenue
Gross Profit
R&D1,3761,2261,7105564036677599127499585056301,172865404350283175374157220446218267112386274301322507601427
SG&A7973911,15242439348046743327724521345242937340647255224149222515755106113160159267229154126188178
Tax0015800000-2100000-400-162-3606-14-12-344-824-8-18-30030
Net Income2,1691,6152,689-976-7121,142-6,219-995-1,008-1,202-715-1,022-1,211-1,234-520-716-752-435-868-379-390459-353-387-206-598-564-5871,289-693-855-668
Cash Flow ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-30
Cash Operating-2,000-3,830-661-463-1,093-1,150-1,008-1,078-940-925-768-1,297-947-624-503-400-626-293-26-511-379-212-49-428-4701,486-475-299-787
Cash Investing000170-376040000000000000000000000
Cash Financing00000000000000001,00000946000-15000500